Exploring Analyst Estimates for Elanco Animal Health (ELAN) Q4 Earnings, Beyond Revenue and EPS

Zacks
24 Feb

Wall Street analysts expect Elanco Animal Health Incorporated (ELAN) to post quarterly earnings of $0.15 per share in its upcoming report, which indicates a year-over-year increase of 87.5%. Revenues are expected to be $1.01 billion, down 2.2% from the year-ago quarter.

Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 2.5% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.

That said, let's delve into the average estimates of some Elanco Animal Health metrics that Wall Street analysts commonly model and monitor.

The combined assessment of analysts suggests that 'Revenue- Total Pet Health' will likely reach $428.67 million. The estimate suggests a change of +3.1% year over year.

Analysts expect 'Revenue- Total Contract Manufacturing' to come in at $9.35 million. The estimate indicates a change of +3.9% from the prior-year quarter.

According to the collective judgment of analysts, 'Revenue- Total Farm Animal' should come in at $575.40 million. The estimate points to a change of -5.7% from the year-ago quarter.

View all Key Company Metrics for Elanco Animal Health here>>>

Shares of Elanco Animal Health have demonstrated returns of -8.8% over the past month compared to the Zacks S&P 500 composite's -0.5% change. With a Zacks Rank #4 (Sell), ELAN is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Elanco Animal Health Incorporated (ELAN) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10